Friday, September 5, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

Making transfusion-transmitted malaria in Europe a thing of the past

April 26, 2024
in Cancer
Reading Time: 4 mins read
0
Making transfusion-transmitted malaria in Europe a thing of the past
66
SHARES
603
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

Individuals requiring blood transfusion are a vulnerable population, often with debilitating conditions like cancer, and transfusion-transmitted malaria is often fatal.

Individuals requiring blood transfusion are a vulnerable population, often with debilitating conditions like cancer, and transfusion-transmitted malaria is often fatal.

Current serological tests used to identify “at risk” donors are not sensitive enough to completely eliminate malaria transfusion risk.

The current challenges are to optimise the testing strategy to minimise the loss of blood products (especially those rare blood phenotypes) and to enhance screening sensitivity for infectious immuno-tolerant donors who are difficult to identify.

**ECCMID has now changed its name to ESCMID Global, please credit ESCMID Global Congress (formerly ECCMID, Barcelona, Spain, 27-30 April) in all future stories**

The current strategy used in Europe to mitigate malaria transfusion risk is efficient with just 10 reported cases over the 20 past years. However, current serological tests used to identify “at risk” donors are not sensitive enough to completely eliminate the risk. In a presentation to be given at this year’s ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April), Dr Sophie Le Cam from the French transfusion blood service (Etablissement Français du Sang [EFS]), will discuss the ongoing efforts being made to prevent transfusion-associated malaria in Europe and outline the different malaria screening strategies that need to be combined in order to ensure the safety of blood transfusions going forward.

Transfusion-transmitted malaria (TTM) is an accidental Plasmodium infection caused by whole blood or a blood component transfusion from a malaria infected donor to a recipient. Just a few parasites in a unit of blood are enough to cause infection, and all Plasmodium species are able to survive in stored blood, even if frozen, and retain their viability for at least a week. Ten cases of TTM have been reported in Europe over the last 20 years, in France, Spain, the UK, Italy, and the Netherlands.

Dr Le Cam highlights an important difference between natural malaria infection and TTM: “When individuals are infected naturally with malaria from a mosquito bite they undergo an initial asymptomatic phase which allows immunity cells to be activated against malaria parasites. But infected blood transfusions directly release malaria parasites into the bloodstream triggering high risk complications that can potentially lead to a fatal outcome, especially in non-endemic countries where the majority of individuals have never been exposed to malaria, and in immuno-compromised patients such as those with cancer and the elderly.”

Europe has a mandatory directive to prevent TTM, which recommend that people who have recently travelled to a country with malaria, or former residents of areas where malaria is present, cannot donate blood for at least 6 months and 3 years after they return, respectively.

In many countries, this deferral period can be reduced to 4 months if a negative malaria test is shown before each donation. However, existing microscopy and serological tests used to mandate these rules are not sensitive enough to reliably mitigate malaria transfusion risk. Microscopic examination is the “gold standard” for diagnosis of malaria illness, but is not adapted to blood bank activities in Europe. Serologic tests are widely used, but their sensitivity and specificity are not as good as expected.

According to Dr Le Cam, “The risk that is most difficult to mitigate comes from donors born, or who lived their early childhood, in malaria-endemic countries who can develop an immune-tolerance—a host response that protects against high numbers of parasite and illness without eliminating the infection.” In these infectious immune-tolerant individuals, cases of TTM have been linked to blood donations given more than 5 years after the last potential exposure of the donor to P. falciparum, and several decades in the case of P. malariae.

As Dr Le Cam explains, “These asymptomatic infections characterised by low parasite densities require more sensitive methods for detection such as recent molecular methods. But while a fully automated molecular method may be the ideal screening method for malaria infection in the blood donor population, it is an expensive option.”

Le Cam sees the current challenge to optimising the testing strategy in non-endemic countries as enhancing screening sensitivity for immuno-tolerant donors without compromising the availability of blood products. “On one hand, the limited number of potentially infected donors requires a cost-effective strategy of blood donor screening, but on the other, the accuracy of screening needs to be optimal for the serious outcomes of TTM in malaria naïve and immuno-compromised recipients”, she says.

What needs to be done to make TMM a thing of the past in Europe? According to Dr Le Cam, “The key to transfusion security remains the deferral period after the return of donors from endemic countries. But we really need to develop new testing strategies. The parasite inactivation of blood using new technologies that are able to selectively inactivate pathogens without damaging cells or plasma could also be a good option, but the technology is not completely reliable for packed red blood cells and is very expensive. Ultimately, different strategies need to be combined in order to ensure the safety of blood transfusions in Europe that include blood donor screening by appropriate diagnostic tools, which should probably include molecular tests.”

 



Article Publication Date

26-Apr-2024

COI Statement

The author declares no conflicts of interest.

Share26Tweet17
Previous Post

Experts developing way to harness Nobel Prize winning CRISPR technology to deal with antimicrobial resistance (AMR)

Next Post

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen

Related Posts

blank
Cancer

MD Anderson and Phoenix SENOLYTIX Forge Strategic Cross-Licensing Partnership to Advance Inducible Switch Technologies in Cell and Gene Therapies

September 5, 2025
blank
Cancer

Breakthrough Discoveries from MD Anderson: Research Highlights – September 5, 2025

September 5, 2025
blank
Cancer

Targeting One Key Factor Could Disrupt Brain Tumors in Two Crucial Ways

September 5, 2025
blank
Cancer

Innovative Innate Immune Checkpoint Inhibitor Demonstrates Efficacy Against Solid Tumors in Rodent Models

September 5, 2025
blank
Cancer

Progesterone Supplementation Promotes Enhanced Breast Growth in Gender-Affirming Hormone Therapy

September 5, 2025
blank
Cancer

Decoding Cancer-Immune Cell Interactions That Propel Breast Cancer Metastasis

September 5, 2025
Next Post
Mpox

Lower dose of mpox vaccine is safe and generates six-week antibody response equivalent to standard regimen

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27544 shares
    Share 11014 Tweet 6884
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    959 shares
    Share 384 Tweet 240
  • Bee body mass, pathogens and local climate influence heat tolerance

    643 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    510 shares
    Share 204 Tweet 128
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    313 shares
    Share 125 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Advancements in Photocatalysis for Pollution Cleanup
  • New Study Reveals Rapid Insect Decline in Pristine Ecosystems
  • Scientists Uncover Vast Geo-Hydrogen Reservoir West of Mussau Trench
  • Unveiling North America’s Influence on Asia’s Monsoons: New Perspectives on Climate Change

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,183 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading